Regulation of the IL-23 and IL-12 Balance by Stat3 Signaling in the Tumor Microenvironment

Cancer Cell

Volumn 15, Issue 2, 2009, Pages 114-123

  Kortylewski, Marcin ^a   Xin, Hong ^a   Kujawski, Maciej ^a   Lee, Heehyoung ^a   Liu, Yong ^a   Harris, Timothy ^b   Drake, Charles ^b   Pardoll, Drew ^b   Yu, Hua ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

CELLCYCLE; MOLIMMUNO

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 23; INTERLEUKIN 23 RECEPTOR; STAT3 PROTEIN; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOGENESIS; CELL TYPE; CONTROLLED STUDY; DENDRITIC CELL; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY;

EID: 58649119388     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2008.12.018     Document Type: Article

References (44)

1. Apetoh L., Ghiringhelli F., Tesniere A., Obeid M., Ortiz C., Criollo A., Mignot G., Maiuri M.C., Ullrich E., Saulnier P., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13 (2007) 1050-1059
2. Chen Z., Laurence A., Kanno Y., Pacher-Zavisin M., Zhu B.M., Tato C., Yoshimura A., Hennighausen L., and O'Shea J.J. Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proc. Natl. Acad. Sci. USA 103 (2006) 8137-8142
3. Colombo M.P., and Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 13 (2002) 155-168
4. Cua D.J., Sherlock J., Chen Y., Murphy C.A., Joyce B., Seymour B., Lucian L., To W., Kwan S., Churakova T., et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421 (2003) 744-748
5. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., and Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3 (2002) 991-998
6. Dunn G.P., Bruce A.T., Sheehan K.C., Shankaran V., Uppaluri R., Bui J.D., Diamond M.S., Koebel C.M., Arthur C., White J.M., and Schreiber R.D. A critical function for type I interferons in cancer immunoediting. Nat. Immunol. 6 (2005) 722-729
7. Garcia-Hernandez M.L., Hernandez-Pando R., Gariglio P., and Berumen J. Interleukin-10 promotes B16-melanoma growth by inhibition of macrophage functions and induction of tumour and vascular cell proliferation. Immunology 105 (2002) 231-243
8. Gerosa F., Baldani-Guerra B., Nisii C., Marchesini V., Carra G., and Trinchieri G. Reciprocal activating interaction between natural killer cells and dendritic cells. J. Exp. Med. 195 (2002) 327-333
9. Ghilardi N., Kljavin N., Chen Q., Lucas S., Gurney A.L., and De Sauvage F.J. Compromised humoral and delayed-type hypersensitivity responses in IL-23-deficient mice. J. Immunol. 172 (2004) 2827-2833
10. Grumont R., Hochrein H., O'Keeffe M., Gugasyan R., White C., Caminschi I., Cook W., and Gerondakis S. c-Rel regulates interleukin 12 p70 expression in CD8(+) dendritic cells by specifically inducing p35 gene transcription. J. Exp. Med. 194 (2001) 1021-1032
11. Harris T.J., Grosso J.F., Yen H.R., Xin H., Kortylewski M., Albesiano E., Hipkiss E.L., Getnet D., Goldberg M.V., Maris C.H., et al. Cutting edge: An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J. Immunol. 179 (2007) 4313-4317
12. Huber M., Steinwald V., Guralnik A., Brustle A., Kleemann P., Rosenplanter C., Decker T., and Lohoff M. IL-27 inhibits the development of regulatory T cells via STAT3. Int. Immunol. 20 (2008) 223-234
13. Kaplan D.H., Shankaran V., Dighe A.S., Stockert E., Aguet M., Old L.J., and Schreiber R.D. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. USA 95 (1998) 7556-7561
14. Kinjyo I., Inoue H., Hamano S., Fukuyama S., Yoshimura T., Koga K., Takaki H., Himeno K., Takaesu G., Kobayashi T., and Yoshimura A. Loss of SOCS3 in T helper cells resulted in reduced immune responses and hyperproduction of interleukin 10 and transforming growth factor-beta 1. J. Exp. Med. 203 (2006) 1021-1031
15. Koebel C.M., Vermi W., Swann J.B., Zerafa N., Rodig S.J., Old L.J., Smyth M.J., and Schreiber R.D. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450 (2007) 903-907
16. Kortylewski M., Kujawski M., Wang T., Wei S., Zhang S., Pilon-Thomas S., Niu G., Kay H., Mule J., Kerr W.G., et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat. Med. 11 (2005) 1314-1321
17. Kryczek I., Wei S., Zou L., Altuwaijri S., Szeliga W., Kolls J., Chang A., and Zou W. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J. Immunol. 178 (2007) 6730-6733
18. Langowski J.L., Zhang X., Wu L., Mattson J.D., Chen T., Smith K., Basham B., McClanahan T., Kastelein R.A., and Oft M. IL-23 promotes tumour incidence and growth. Nature 442 (2006) 461-465
19. Langowski J.L., Kastelein R.A., and Oft M. Swords into plowshares: IL-23 repurposes tumor immune surveillance. Trends Immunol. 28 (2007) 207-212
20. Langrish C.L., Chen Y., Blumenschein W.M., Mattson J., Basham B., Sedgwick J.D., McClanahan T., Kastelein R.A., and Cua D.J. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201 (2005) 233-240
21. Laurence A., Tato C.M., Davidson T.S., Kanno Y., Chen Z., Yao Z., Blank R.B., Meylan F., Siegel R., Hennighausen L., et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 26 (2007) 371-381
22. Murphy C.A., Langrish C.L., Chen Y., Blumenschein W., McClanahan T., Kastelein R.A., Sedgwick J.D., and Cua D.J. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J. Exp. Med. 198 (2003) 1951-1957
23. Oppmann B., Lesley R., Blom B., Timans J.C., Xu Y., Hunte B., Vega F., Yu N., Wang J., Singh K., et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13 (2000) 715-725
24. O'Shea J.J., and Murray P.J. Cytokine signaling modules in inflammatory responses. Immunity 28 (2008) 477-487
25. Pallandre J.R., Brillard E., Crehange G., Radlovic A., Remy-Martin J.P., Saas P., Rohrlich P.S., Pivot X., Ling X., Tiberghien P., and Borg C. Role of STAT3 in CD4+CD25+FOXP3+ regulatory lymphocyte generation: implications in graft-versus-host disease and antitumor immunity. J. Immunol. 179 (2007) 7593-7604
26. Parham C., Chirica M., Timans J., Vaisberg E., Travis M., Cheung J., Pflanz S., Zhang R., Singh K.P., Vega F., et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J. Immunol. 168 (2002) 5699-5708
27. Shankaran V., Ikeda H., Bruce A.T., White J.M., Swanson P.E., Old L.J., and Schreiber R.D. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410 (2001) 1107-1111
28. Stumhofer J.S., Silver J.S., Laurence A., Porrett P.M., Harris T.H., Turka L.A., Ernst M., Saris C.J., O'Shea J.J., and Hunter C.A. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat. Immunol. 8 (2007) 1363-1371
29. Sutmuller R.P., van Duivenvoorde L.M., van Elsas A., Schumacher T.N., Wildenberg M.E., Allison J.P., Toes R.E., Offringa R., and Melief C.J. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194 (2001) 823-832
30. Takeda K., Clausen B.E., Kaisho T., Tsujimura T., Terada N., Forster I., and Akira S. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10 (1999) 39-49
31. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3 (2003) 133-146
32. Turk M.J., Guevara-Patino J.A., Rizzuto G.A., Engelhorn M.E., Sakaguchi S., and Houghton A.N. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J. Exp. Med. 200 (2004) 771-782
33. Wan Y.Y., and Flavell R.A. Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. Nature 445 (2007) 766-770
34. Wang J., Wang X., Hussain S., Zheng Y., Sanjabi S., Ouaaz F., and Beg A.A. Distinct roles of different NF-kappa B subunits in regulating inflammatory and T cell stimulatory gene expression in dendritic cells. J. Immunol. 178 (2007) 6777-6788
35. Wang T., Niu G., Kortylewski M., Burdelya L., Shain K., Zhang S., Bhattacharya R., Gabrilovich D., Heller R., Coppola D., et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med. 10 (2004) 48-54
36. Wei L., Laurence A., Elias K.M., and O'Shea J.J. IL-21 is produced by TH17 cells and drives IL-17 production in a STAT3-dependent manner. J. Biol. Chem. 282 (2007) 34605-34610
37. Yao Z., Kanno Y., Kerenyi M., Stephens G., Durant L., Watford W.T., Laurence A., Robinson G.W., Shevach E.M., Moriggl R., et al. Nonredundant roles for Stat5a/b in directly regulating Foxp3. Blood 109 (2007) 4368-4375
38. Yu H., and Jove R. The STATs of cancer--new molecular targets come of age. Nat. Rev. Cancer 4 (2004) 97-105
39. Yu H., Kortylewski M., and Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 7 (2007) 41-51
40. Zheng Y., Danilenko D.M., Valdez P., Kasman I., Eastham-Anderson J., Wu J., and Ouyang W. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445 (2007) 648-651
41. Zhou L., Ivanov I.I., Spolski R., Min R., Shenderov K., Egawa T., Levy D.E., Leonard W.J., and Littman D.R. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat. Immunol. 8 (2007) 967-974
42. Zorn E., Nelson E.A., Mohseni M., Porcheray F., Kim H., Litsa D., Bellucci R., Raderschall E., Canning C., Soiffer R.J., et al. IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 108 (2006) 1571-1579
43. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5 (2005) 263-274
44. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6 (2006) 295-307